small lymphocytic lymphoma (SLL)

October 29, 2019

Copiktra Superior to Arzerra for CLL/SLL Patients with Prior Therapies, Data Suggest

News

Treatment with Copiktra (duvelisib) doubles response rates compared with Arzerra (ofatumumab), and significantly extends the time until disease progression or death in people with chronic lymphocytic leukemia (CLL) or small ... Read more

January 24, 2019

Imbruvica-Opdivo Combination Shows Promise in Richter’s Transformation

News

A combination of Imbruvica (ibrutinib) and Opdivo (nivolumab) reduced tumor burden in 65% of patients with Richter’s transformation — a kind of diffuse large B-cell lymphoma (DLBCL) with very poor prognosis, derived ... Read more

January 21, 2019

LOXO-305 Trial Begins for Lymphoma, Leukemia Patients Resistant to BTK Inhibitors

News

A Phase 1/2 trial is evaluating Loxo Oncology‘s BTK inhibitor LOXO-305 in leukemia and lymphoma patients who failed, or were intolerant to, approved BTK inhibitors. The trial, so far being conducted ... Read more

October 23, 2018

FDA Grants Priority Review to Imbruvica-Gazyva Combo for First-line Treatment of CLL/SLL

News

The U.S. Food and Drug Administration has granted priority review to AbbVie‘s application seeking the approval of Imbruvica (ibrutinib) plus Gazyva (obinutuzumab) for patients with chronic lymphocytic leukemia or small lymphocytic ... Read more

June 12, 2017June 12, 2017

Imbruvica Seen to Improve Long-Term Survival in Certain Leukemia Patients, Trial Data Show

News

People with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic leukemia (CLL/SLL) who were treated with Imbruvica (ibrutinib) in a clinical trial — and then followed for several years — ... Read more